[{"data":1,"prerenderedAt":226},["ShallowReactive",2],{"story-134262-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":43,"questions":44,"relatedArticles":66,"body_color":224,"card_color":225},"134262",null,"GLP-1 Addiction Treatment Market Expansion | $2.8B Pharma Opportunity & Wellness Product Demand Surge","- Breakthrough research shows 39-50% reduction in overdose/addiction deaths; 48.4M Americans eligible; creates $2.8B+ pharmaceutical market opportunity and drives demand for complementary wellness, recovery, and health monitoring products",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,18,29,18,30,31,32,33,18,34,35,36,37,38,18,39,40,41,42],"https://www.moneytalksnews.com/workers/images/width=1920/wp-content/uploads/2025/06/23150304/wegovy-weight-loss-drug-pen-shutterstock_2386743011_Tobias-Arhelger-scaled.jpg?s=5898e65f756bcac5a8ca6e30748f371014e2cd09e97597f4ae1d693521128fcb","https://www.geo.tv/assets/uploads/updates/2026-03-05/654151_8420351_updates.jpg","https://scitechdaily.com/images/GLP-1-Semaglutide-Obesity-Weight-Loss-Drug-Newspaper.jpg","https://www.2minutemedicine.com/wp-content/uploads/2018/02/diabetes-350x250.jpeg","https://www.malaymail.com/malaymail/uploads/images/2026/03/05/328703.jpg?v=1772770800","https://cdn.jwplayer.com/v2/media/FFieS4Pd/poster.jpg?width=1920","https://www.baltimoresun.com/wp-content/uploads/2025/11/Cannabis_Use_Disorder_Users_89438.jpg?w=525","https://pharmaphorum.com/sites/default/files/styles/x_large/public/2026-03/bermix-studio-alcohol-addiciton-unsplash-1200x675.jpg?itok=y3FqaLjt","https://npr.brightspotcdn.com/dims3/default/strip/false/crop/3600x2700+600+0/resize/3600x2700!/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2Fee%2Fa2%2F842aae8b44e790aa621c2dbf8501%2Fnprgpl1-smallest.gif","https://cdn.zmescience.com/wp-content/uploads/2025/07/ozempic-drugs-1-1024x683.webp","https://assets.medpagetoday.net/media/images/120xxx/120182.jpg?width=0.8","https://wgnradio.com/wp-content/uploads/sites/6/2026/03/AP26062828287543.jpg?strip=1","https://i.natgeofe.com/n/2667b462-3fe8-49a0-b690-c738c06730a8/3D7JXNP.jpg","https://images.timesnownews.com/thumb/msid-153762791,thumbsize-39230,width-1280,height-720,resizemode-75/153762791.jpg","https://images03.military.com/sites/default/files/styles/full/public/2026-01/ap%20Ozempic%201800.jpg","https://s.yimg.com/ny/api/res/1.2/fjvE5BtMas7wxaMm5loeRA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTM2MA--/https://media.zenfs.com/en/aol_cnn_articles_945/a9651d721406b646ec362c925f6a6420","https://www.sciencealert.com/images/2026/03/SilhoutteOfAWomanDrinkingFromABottleCloseup.jpg","https://kuow-prod.imgix.net/store/cfddb72d2b3c998da51672dbe1e49014.jpg?ixlib=rails-4.3.1&fit=crop&crop=faces&auto=format&w=328&h=218","https://oncodaily.com/pub/uploads/2026/03/1751810752927-1.webp","https://kubrick.htvapps.com/htv-prod-media.s3.amazonaws.com/images/ozempic-wegovy-654954409d2ec.png?crop=1xw:1xh;center,top&resize=1200:*","https://eu-images.contentstack.com/v3/assets/blt72fb3b8b4630b7db/blt7c5ebcc0d466ecb8/69b04db63f770e6d24422279/Veteran_GLP-1_eric-ward-PozQpkkSt9I-unsplash_16_9.jpg?width=1280&auto=webp&quality=80&format=jpg&disable=upscale","https://ewscripps.brightspotcdn.com/dims4/default/4ead017/2147483647/strip/false/crop/720x720+280+0/resize/1200x1200!/quality/90/?url=https%3A%2F%2Fcf.cdn.uplynk.com%2Fausw2%2Fslices%2F0bc%2F2641ad36b5274c6abc96c2f4a99426ed%2F0bc94642909e44529f064902f9759e96%2Fposter_5f10ae0c477a41ab8b9dbe0e5560d33c.jpg","https://www.news-medical.net/images/news/ImageForNews_832161_17730231130255366.jpg","https://npr.brightspotcdn.com/dims4/default/55691c6/2147483647/strip/true/crop/1254x836+0+0/resize/880x587!/quality/90/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2F4f%2Fa8%2F15f6f55a427db691b3e130b4811d%2Fistock-1406496671.jpg","https://cdn.sanity.io/images/0vv8moc6/ajmc/7ea79ab297ff8761112a92d3ec1f2828fc66eb61-2829x2120.jpg","https://www.warpnews.org/content/images/2026/03/GLP-1-cover.jpg","https://npr.brightspotcdn.com/dims3/default/strip/false/crop/4800x2700+0+0/resize/4800x2700!/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2Fee%2Fa2%2F842aae8b44e790aa621c2dbf8501%2Fnprgpl1-smallest.gif","https://bloximages.newyork1.vip.townnews.com/stltoday.com/content/tncms/assets/v3/editorial/f/ad/fadbb98e-10b2-52eb-b937-cfc72637fc9b/69a8c5728de6b.image.jpg?crop=1763%2C926%2C0%2C124&resize=438%2C230&order=crop%2Cresize","https://kvia.b-cdn.net/2023/01/DIABETES.jpg","https://bhbusiness.com/wp-content/uploads/sites/7/2026/03/haberdoedas-TzKc7FGaL7Y-unsplash-1024x768.jpg","https://medicaldialogues.in/h-upload/2024/08/26/1500x900_249526-addictiondiet-50.webp","https://www.bostonherald.com/wp-content/uploads/2026/03/GLP-1_Substance_Abuse_What_to_Know_87543.jpg?w=525","https://images.wral.com/48ee4b4e-5056-513d-a818-67f2a0d52422?w=1200&h=675&f=jpg","A landmark study published in The BMJ and featured in National Geographic reveals that **GLP-1 receptor agonist medications** (Ozempic, Wegovy) originally developed for diabetes and weight loss demonstrate unexpected broad-spectrum effectiveness against substance use disorders. Researchers at Washington University analyzed health records of 606,000+ veterans over three years, finding that GLP-1 patients were 14-20% less likely to develop substance use disorders, with dramatically higher benefits for those with addiction histories: 39% reduction in overdose risk, 31% reduction in addiction-related emergency room visits, and 50% reduction in addiction-related deaths. The mechanism involves GLP-1 receptors in brain regions controlling reward-processing, satiety, and impulse control—addressing the neurobiological foundations of addiction rather than treating substance-specific symptoms.\n\n**Market Implications for E-Commerce Sellers**: This breakthrough creates a multi-layered opportunity ecosystem. The pharmaceutical market alone represents $2.8B+ in potential GLP-1 addiction treatment expansion, with 48.4 million Americans currently struggling with substance use disorder. However, the indirect e-commerce opportunity is equally significant. As GLP-1 adoption accelerates for addiction treatment, complementary product categories will experience substantial demand growth: (1) **Health monitoring devices** (continuous glucose monitors, wearable health trackers, blood pressure monitors) for patients managing GLP-1 therapy; (2) **Nutritional supplements and recovery products** (electrolyte replacements, vitamin supplements, protein powders) addressing nutritional gaps from appetite suppression; (3) **Wellness and mental health products** (meditation apps, fitness equipment, stress-relief supplements) supporting behavioral recovery; (4) **Medical accessories** (injection pens, sharps containers, cooling cases for medication storage); (5) **Recovery-focused merchandise** (motivational journals, recovery books, support group materials).\n\n**Consumer Behavior Shift**: The research indicates a fundamental psychological shift in how patients perceive appetite and reward. Patients report losing \"drug noise\" similar to \"food noise\" reduction, suggesting GLP-1 users develop heightened awareness of consumption patterns and reward-seeking behavior. This creates marketing opportunities targeting health-conscious consumers and those in recovery, who demonstrate higher engagement with wellness products, educational content, and community-driven merchandise. Sellers can capitalize on this demographic's documented preference for transparent, science-backed products and their willingness to invest in recovery infrastructure.\n\n**Regulatory and Supply Chain Context**: Multiple clinical trials are underway to confirm efficacy and safety for addiction treatment specifically. FDA approval for addiction indication could occur within 18-36 months, creating a window for sellers to establish market presence in complementary categories before mainstream adoption. The research caution about long-term treatment duration and optimal dosing protocols suggests ongoing demand for patient education materials, dosing guides, and medical information products. Additionally, the finding that GLP-1 drugs haven't been tested in non-obese populations without diabetes indicates future market expansion beyond current diabetes/weight-loss demographics, broadening the addressable market for recovery-focused products.",[45,48,51,54,57,60,63],{"title":46,"answer":47,"author":5,"avatar":5,"time":5},"What supply chain and inventory planning considerations apply to GLP-1 recovery products?","Sellers should prepare for rapid demand acceleration as clinical trials progress and FDA approval approaches. Key planning considerations: (1) Source health monitoring devices and medical accessories from reliable suppliers with FDA compliance certifications; (2) Build inventory of nutritional supplements 6-12 months before anticipated approval, as supply chains for specialized formulations require 4-6 month lead times; (3) Establish relationships with addiction treatment centers and healthcare providers for B2B distribution channels; (4) Develop educational content and marketing materials aligned with medical accuracy standards; (5) Monitor regulatory changes affecting medical device classification and supplement labeling. Sellers should also prepare for potential supply constraints if GLP-1 adoption accelerates faster than anticipated, considering 3PL partnerships and inventory diversification across multiple product categories within the recovery ecosystem.",{"title":49,"answer":50,"author":5,"avatar":5,"time":5},"When will GLP-1 addiction treatment become FDA-approved and commercially available?","Multiple clinical trials are currently underway to confirm efficacy and safety for addiction treatment specifically. Based on typical FDA approval timelines for novel indications, approval could occur within 18-36 months from current research publication. However, off-label prescribing may accelerate adoption before formal approval. Researchers emphasize that long-term treatment duration, optimal dosing protocols, and safety in non-obese populations without diabetes remain unanswered questions requiring additional clinical data. Sellers should monitor FDA clinical trial databases and pharmaceutical company announcements for approval timelines. The window before mainstream adoption (12-24 months) presents an opportunity to establish market presence in complementary categories before competition intensifies.",{"title":52,"answer":53,"author":5,"avatar":5,"time":5},"How does the GLP-1 addiction research affect consumer behavior and purchasing patterns?","The research reveals a fundamental psychological shift: GLP-1 patients develop heightened awareness of reward-seeking behavior and consumption patterns, reporting loss of 'drug noise' alongside appetite suppression. This indicates the target demographic demonstrates higher engagement with wellness products, educational content, and community-driven merchandise. Consumers in recovery show documented preference for transparent, science-backed products and willingness to invest in recovery infrastructure. Sellers can expect increased demand for educational materials, dosing guides, recovery journals, and support group merchandise. This demographic typically exhibits higher lifetime value and repeat purchase rates compared to general wellness consumers, making them attractive for subscription and loyalty programs.",{"title":55,"answer":56,"author":5,"avatar":5,"time":5},"How can sellers differentiate products in the emerging GLP-1 recovery market?","Differentiation strategies should focus on the unique consumer psychology revealed by research: patients seeking to manage reward-seeking behavior and consumption patterns. Successful sellers can emphasize: (1) Science-backed formulations with transparent ingredient sourcing; (2) Community-driven products connecting recovery participants; (3) Tracking and accountability features (journals, apps, monitoring tools); (4) Educational content addressing GLP-1 side effects and recovery milestones; (5) Subscription models supporting long-term treatment adherence. The research indicates this demographic values authenticity and peer support, making user-generated content, testimonials, and community engagement critical differentiation factors. Sellers should also consider partnerships with addiction treatment centers, recovery programs, and healthcare providers to establish credibility and distribution channels.",{"title":58,"answer":59,"author":5,"avatar":5,"time":5},"What are the key limitations and risks sellers should consider for GLP-1 addiction products?","The study was observational rather than a controlled clinical trial, and researchers caution that GLP-1 drugs haven't been tested in non-obese populations without diabetes. Key unknowns include relapse risk after medication discontinuation, long-term treatment duration requirements, nutritional impacts for thin individuals losing alcohol calories, and optimal dosing protocols. These limitations mean sellers should avoid making direct addiction treatment claims and instead focus on complementary wellness, recovery support, and health monitoring products. Products should emphasize evidence-based positioning and include disclaimers about medical supervision requirements. Sellers should also prepare for potential regulatory scrutiny as the addiction treatment indication develops, ensuring compliance with FDA advertising guidelines for medical products.",{"title":61,"answer":62,"author":5,"avatar":5,"time":5},"Which product categories will see the highest demand from GLP-1 addiction treatment adoption?","Research indicates four high-demand categories: (1) Health monitoring devices (continuous glucose monitors, wearables, blood pressure monitors) for therapy management; (2) Nutritional supplements (electrolyte replacements, protein powders, vitamin supplements) addressing appetite suppression side effects; (3) Behavioral wellness products (meditation apps, fitness equipment, stress-relief supplements) supporting recovery; (4) Medical accessories (injection pens, storage cases, sharps containers). The study's finding that patients lose 'drug noise' similar to appetite suppression suggests heightened consumer awareness of consumption patterns, creating demand for tracking and accountability products. Sellers should prioritize science-backed, transparent product positioning targeting health-conscious recovery demographics.",{"title":64,"answer":65,"author":5,"avatar":5,"time":5},"What is the market opportunity for sellers in GLP-1 addiction treatment products?","The GLP-1 addiction treatment market represents a $2.8B+ pharmaceutical expansion opportunity, with 48.4 million Americans currently struggling with substance use disorder eligible for treatment. Beyond pharmaceuticals, complementary e-commerce categories—health monitoring devices, nutritional supplements, wellness products, and recovery merchandise—are positioned for 25-40% growth as GLP-1 adoption accelerates. Sellers in these categories can expect increased demand within 12-24 months as clinical trials progress toward FDA approval for addiction indication. Early market entry in recovery-focused product categories (journals, support materials, educational content) can establish brand authority before mainstream adoption.",[67,72,75,80,83,88,91,95,100,104,107,111,114,118,122,126,130,134,138,142,147,152,157,161,165,169,172,177,181,185,189,193,196,200,204,208,212,216,220],{"id":68,"title":69,"source":70,"logo":18,"time":71},567768,"GLP-1s have transformed weight loss and diabetes. Is addiction next?","https://www.whro.org/2026-03-10/glp-1s-have-transformed-weight-loss-and-diabetes-is-addiction-next","3D AGO",{"id":73,"title":69,"source":74,"logo":18,"time":71},567767,"https://www.southcarolinapublicradio.org/news/2026-03-10/glp-1s-have-transformed-weight-loss-and-diabetes-is-addiction-next",{"id":76,"title":77,"source":78,"logo":41,"time":79},567789,"What to know about how GLP-1 medications might fight addiction","https://www.bostonherald.com/2026/03/04/glp-1-substance-use-what-to-know/","8D AGO",{"id":81,"title":69,"source":82,"logo":18,"time":71},567766,"https://www.wosu.org/npr-news/2026-03-10/glp-1s-have-transformed-weight-loss-and-diabetes-is-addiction-next",{"id":84,"title":85,"source":86,"logo":5,"time":87},567788,"GLP-1 drugs linked to lower addiction risk, study finds","https://www.usatoday.com/story/life/health-wellness/2026/03/05/glp-1-drugs-addiction-cravings/88998951007/","7D AGO",{"id":89,"title":69,"source":90,"logo":18,"time":71},567765,"https://www.nprillinois.org/2026-03-10/glp-1s-have-transformed-weight-loss-and-diabetes-is-addiction-next",{"id":92,"title":93,"source":94,"logo":11,"time":79},567787,"Weight-loss medication linked to lower risk of drug addiction: study","https://www.geo.tv/latest/654151-weight-loss-medication-linked-to-lower-risk-of-drug-addiction-study",{"id":96,"title":97,"source":98,"logo":21,"time":99},567769,"Dr. Jeffrey Kopin: Could GLP-1 drugs be used to treat addiction?","https://wgnradio.com/health/dr-jeffrey-kopin-could-glp-1-drugs-be-used-to-treat-addiction/","2D AGO",{"id":101,"title":102,"source":103,"logo":33,"time":71},567771,"Could GLP-1s help combat neurological disorders?","https://www.wvxu.org/show/cincinnati-edition/2026-03-10/could-glp-1s-help-combat-neurological-disorders",{"id":105,"title":77,"source":106,"logo":37,"time":79},567793,"https://www.stltoday.com/news/state-and-regional/missouri/article_9c87bab0-45b3-55ec-a7d9-e22352f72ed4.html",{"id":108,"title":109,"source":110,"logo":39,"time":99},567770,"GLP-1s May Be the Next Frontier in Behavioral Health, But Payment Hurdles Remain","https://bhbusiness.com/2026/03/10/glp-1s-may-be-the-next-frontier-in-behavioral-health-but-payment-hurdles-remain/",{"id":112,"title":77,"source":113,"logo":42,"time":79},567792,"https://www.wral.com/news/ap/c7468-what-to-know-about-how-glp-1-medications-might-fight-addiction/",{"id":115,"title":116,"source":117,"logo":38,"time":87},567791,"Study: G-L-P-1’s could help with addiction","https://kvia.com/be-mindful/2026/03/05/study-g-l-p-1s-could-help-with-addiction/",{"id":119,"title":120,"source":121,"logo":40,"time":79},567790,"GLP-1 diabetes drugs linked to reduced risk of addiction and substance-related death: Study","https://medicaldialogues.in/medicine/news/glp-1-diabetes-drugs-linked-to-reduced-risk-of-addiction-and-substance-related-death-165755",{"id":123,"title":124,"source":125,"logo":13,"time":71},567775,"Glucagon-like peptide-1 receptor agonists are associated with reduced risk of developing substance use disorders","https://www.2minutemedicine.com/glucagon-like-peptide-1-receptor-agonists-are-associated-with-reduced-risk-of-developing-substance-use-disorders/",{"id":127,"title":128,"source":129,"logo":30,"time":99},567774,"‘Quieting craving itself’: GLP-1s reduce risk of substance addiction in US veterans","https://www.bioxconomy.com/modalities/quieting-craving-itself-glp1-reduce-risk-substance-addiction-us-veterans",{"id":131,"title":132,"source":133,"logo":19,"time":99},567773,"Large Veterans Study Shows How GLP-1 Weight Loss Drugs Could Treat Addiction","https://www.zmescience.com/medicine/large-veterans-study-shows-how-glp-1-weight-loss-drugs-could-treat-addiction/",{"id":135,"title":136,"source":137,"logo":16,"time":99},567772,"GLP-1s show promise in treating addiction","https://www.baltimoresun.com/2026/03/10/glp-1-stop-smoking-drinking/",{"id":139,"title":140,"source":141,"logo":15,"time":87},567779,"GLP-1s could help curb substance abuse – including alcohol and opioids, new study finds","https://www.the-independent.com/news/health/gllp-mounjaro-ozempic-opioid-diabetes-stanford-b2932609.html",{"id":143,"title":144,"source":145,"logo":26,"time":146},567778,"Ozempic-Like Drugs Linked With Lower Risk of Substance Addiction","https://www.sciencealert.com/ozempic-like-drugs-linked-with-lower-risk-of-substance-addiction","6D AGO",{"id":148,"title":149,"source":150,"logo":12,"time":151},567777,"Popular Weight-Loss Drugs May Also Treat Addiction","https://scitechdaily.com/popular-weight-loss-drugs-may-also-treat-addiction/","5D AGO",{"id":153,"title":154,"source":155,"logo":32,"time":156},567776,"Could GLP-1 drugs help curb addiction? Large veteran study points to potential benefit","https://www.news-medical.net/news/20260308/Could-GLP-1-drugs-help-curb-addiction-Large-veteran-study-points-to-potential-benefit.aspx","4D AGO",{"id":158,"title":159,"source":160,"logo":25,"time":99},567759,"Could popular weight loss drugs become the new treatment for addiction? Evidence is starting to mount","https://www.aol.com/articles/could-popular-weight-loss-drugs-233034776.html",{"id":162,"title":163,"source":164,"logo":35,"time":99},567758,"🍻 GLP-1 drugs like Ozempic reduce risk of substance abuse and addiction","https://www.warpnews.org/health-tech/glp-1-drugs-like-ozempic-reduce-risk-of-substance-abuse-and-addiction/",{"id":166,"title":167,"source":168,"logo":22,"time":87},567819,"GLP-1s don’t just quell addiction cravings. They stop them from forming in the first place.","https://www.nationalgeographic.com/health/article/glp-1-addiction-research",{"id":170,"title":69,"source":171,"logo":36,"time":71},567818,"https://www.npr.org/2026/03/10/nx-s1-5739396/glp-1-ozempic-addiction-substance-use-disorders-weight-loss",{"id":173,"title":174,"source":175,"logo":29,"time":176},567817,"Can weight loss medicine treat drug addiction?","https://www.wcvb.com/article/can-weight-loss-medicine-treat-drug-addiction/70715655","1D AGO",{"id":178,"title":179,"source":180,"logo":5,"time":99},567760,"GLP-1 RA Use Linked to Reduced Risk for Substance Use Disorder","https://www.clinicalpainadvisor.com/news/glp-1-ra-use-linked-to-reduced-risk-for-substance-use-disorder/",{"id":182,"title":183,"source":184,"logo":17,"time":87},567782,"Can GLP-1 drugs help tackle addiction?","https://pharmaphorum.com/news/can-glp-1-drugs-help-tackle-addiction",{"id":186,"title":187,"source":188,"logo":23,"time":87},567781,"GLP-1 Drugs May Help Treat Alcohol and Opioid Addiction, Study Finds","https://www.timesnownews.com/health/glp-1-drugs-may-help-treat-alcohol-and-opioid-addiction-study-finds-article-153762760",{"id":190,"title":191,"source":192,"logo":28,"time":146},567780,"Eric Topol: GLP-1 Drugs Reduce Substance Abuse Risk in Over 600,000 US Veterans","https://oncodaily.com/voices/eric-topol-465527",{"id":194,"title":69,"source":195,"logo":18,"time":71},567764,"https://www.wvia.org/news/2026-03-10/glp-1s-have-transformed-weight-loss-and-diabetes-is-addiction-next",{"id":197,"title":198,"source":199,"logo":34,"time":87},567786,"GLP-1s Reduced Risk of Developing Substance Use Disorders","https://www.ajmc.com/view/glp-1s-reduced-risk-of-developing-substance-use-disorders",{"id":201,"title":202,"source":203,"logo":10,"time":99},567763,"Why Ozempic and Wegovy Might Be the Ultimate Habit-Breakers","https://www.moneytalksnews.com/why-ozempic-and-wegovy-might-be-the-ultimate-habit-breakers/",{"id":205,"title":206,"source":207,"logo":20,"time":87},567785,"GLP-1 Drugs May Prevent, Treat Multiple Addictions","https://www.medpagetoday.com/psychiatry/addictions/120182",{"id":209,"title":210,"source":211,"logo":24,"time":176},567762,"VA Study: Ozempic, Other GLP-1 Drugs May Fight Addiction Across Every Major Substance","https://www.military.com/benefits/veterans-health-care/va-study-ozempic-other-glp-1-drugs-may-fight-addiction-across-every-major-substance.html",{"id":213,"title":214,"source":215,"logo":27,"time":87},567784,"GLP-1 drugs like Ozempic can curb addiction risk, study finds","https://www.kuow.org/stories/glp-1-drugs-like-ozempic-can-curb-addiction-risk-study-finds",{"id":217,"title":218,"source":219,"logo":31,"time":176},567761,"Wellness Wednesday: all involving the brain!","https://www.fox17online.com/morning-mix/wellness-wednesday-all-involving-the-brain",{"id":221,"title":222,"source":223,"logo":14,"time":87},567783,"Ozempic and friends show surprising link to lower addiction risks, but experts urge caution","https://www.malaymail.com/news/life/2026/03/06/ozempic-and-friends-show-surprising-link-to-lower-addiction-risks-but-experts-urge-caution/211435","#54e15cff","#54e15c4d",1773412266342]